Zwitterionic Lipids for Nucleic Acid Delivery
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for producing liposomes on a large scale face challenges in controlling liposome diameter and the amount of encapsulated bioactive substance, particularly with zwitterionic lipids, which are essential for reliable engineering of parameters such as liposome diameter and bioactive delivery.
Innovation Solution
Development of novel transiently cationic zwitterionic lipids and particles that form small bilayer structures, capable of encapsulating bioactive agents and delivering them into the cytoplasm, while maintaining low cytotoxicity and reduced immunoreactivity, using a family of zwitterionic lipids with a quaternary ammonium moiety and carboxylic acid moiety, and betaine headgroups that become cationic at acidic pH.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Manufacturing precision
If conventional lipid hydration methods are used for large-scale liposome production, then liposomes can be formed, but reliable control of liposome diameter and encapsulated bioactive substance amount is difficult
Solution Approach 1:
The patent employs parameter changes by modifying the lipid composition to include specific ratios of zwitterionic lipids (30-70 mol%), cationic lipids (10-40 mol%), and helper lipids (10-40 mol%). By adjusting these compositional parameters and the cholesterol content (5-50 mol%), the invention achieves reliable control over liposome diameter (30-300 nm) and encapsulation efficiency while maintaining scalability for large-scale production.
2Reliability
If cationic lipids are used to deliver nucleic acids, then encapsulation efficiency improves, but cytotoxicity and immunoreactivity increase
Solution Approach 1:
The patent applies local quality by creating a spatially differentiated charge distribution on the liposome surface. The zwitterionic lipids provide a neutral outer surface that reduces immune recognition, while cationic lipids localized within the bilayer maintain strong electrostatic attraction for negatively charged nucleic acids. This localized arrangement allows efficient nucleic acid encapsulation while minimizing cytotoxicity and immunoreactivity associated with uniformly cationic surfaces.
Solution Approach 2:
The invention uses composite lipid materials combining zwitterionic lipids (reducing toxicity), cationic lipids (providing nucleic acid binding), and helper lipids (facilitating endosomal escape). This composite approach creates a synergistic system where each lipid type contributes specific functions, achieving effective gene delivery with reduced harmful effects compared to using cationic lipids alone.
3Productivity
If liposomes are made smaller to improve cellular uptake, then delivery efficiency increases, but encapsulation capacity decreases
Solution Approach 1:
The patent employs multiple copying of the lipid bilayer structure to create multilamellar vesicles (MLVs) where multiple concentric bilayers provide cumulative encapsulation capacity. Each bilayer copy contributes to both the structural integrity for cellular uptake and the total volume available for nucleic acid encapsulation, thus maintaining high delivery efficiency while increasing overall cargo capacity.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
These zwitterionic lipids enable efficient cytoplasmic DNA and RNA delivery, facilitating high gene transfer and mRNA knockdown with reduced immune stimulatory toxicity, providing a unique platform for nucleic acid carriers and improving the encapsulation efficiency and delivery of bioactive agents.
Implementation Method 1
Lipids with transiently cationic headgroups can convert into a non-lamellar phase upon a change in pH... betaine headgroups that become cationic at acidic pH
Implementation Method 2
Liposomes are small vesicles composed of amphipathic lipids arranged in spherical bilayers... lipids that disperse in aqueous solution and form small (30-300 nm) bilayer structures
Implementation Method 3
Liposomes may be used to encapsulate various materials, by trapping hydrophilic compounds in the aqueous interior or between bilayers, or by trapping hydrophobic compounds within the bilayer
Data Source
AI summary
In various embodiments, the present invention provides zwitterionic lipids, encapsulants incorporating these zwitterionic lipids and such encapsulants encapsulating one or more bioactive agent. An exemplary bioactive agent is a nucleic acid. Also provided are pharmaceutical formulations of the encapsulants and methods of using such formulations to deliver a bioactive agent to a subject in treating or diagnosing disease in that subject.